Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double | Global News Avenue

Novo Nordisk’s (NGOsU.S.-listed stocks rose 4% on Wednesday after “enhanced competition” compared to the estimated quarter of Ozempic and Wegovy Maker.

Ozempic and Wegovy, a manufacturer of large-scale weight loss pills, reported sales in the fourth quarter rose 30% year-on-year to 85.68 billion Danish Kron ($11.97 billion), more than the visible Alpha compilation analyst estimates 80.62 billion dkk. Novo Nordisk’s $2823 billion profit also exceeded estimates.

Wegovy’s sales soared 107% at a constant exchange rate to 19.87 billion dkk, below estimates. Ozempic sales rose 12% to 3.85 billion dkk, higher than expected.

Novo Nordisk sees sales growth of 16% to 24% in 2025

However, Supply Limits And the growing competition is giving it prospects. Novo Nordisk expects sales to grow 16% to 24% in 2025 at a constant exchange rate, down from the 26% increase generated in 2024.

Novo Nordisk said the guide reflects “intensifying competition and continuing pricing pressures in diabetes and obesity.” The company is Weight loss medication space With Mounjaro and Zepbough Maker Eli Lilly (LiberalTo.

“In 2025, we will continue to focus on commercial execution, the development of our early and late R&D pipelines and the expansion of our production capacity,” said CEO Lars Fruergaard Jorgensen.

Novo Nordisk listed stocks have been low Since September,fall In December After the test results, its weight loss pill cagrisema was disappointed. The Danish company said on Wednesday that it plans to submit ocean approvals in the first quarter of the first quarter, “to ensure supply chain preparation.”